Phase II multi-institutional study of nivolumab (Nivo), cabiralizumab (Cabira), and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer (LAUPC).

Authors

Deirdre Jill Cohen

Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY

Deirdre Jill Cohen , Benjamin Medina , Kevin Lee Du , Andrew L. Coveler , Gulam Abbas Manji , Paul Eliezer Oberstein , Serena K Perna , George Miller

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

GRECO-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with rucosopasem (GC4711) in the treatment of locally advanced or borderline resectable nonmetastatic pancreatic cancer.

First Author: Sarah E. Hoffe

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Preliminary results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc) for the non-L sarcoma cohort.

First Author: Daniel Pink

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.

First Author: Manish A. Shah

insert_chart_outlined

Poster

2016 Gastrointestinal Cancers Symposium

bookmark_border

Phase II study of nivolumab (ONO-4538/BMS-936558) in patients with esophageal cancer: Preliminary report of overall survival.

First Author: Takashi Kojima